Smithkline Beecham Corporation

Glaxosmithkline LLC

Other

Glaxosmithkline Intellectual Property Development Limited

Kyung Oh Johanson

Zdenka Ludmila Jonak

Alexander H Taylor

Robert B Kirkpatrick

Stephen H Trulli

Narendra B Bam

Cheryl Ann Janson

Peter Lawrence DeMarsh

Jacob Bongers

Xianyang Qiu

Ping Yeh

Allan R Shatzman

Alexander Harrison Taylor

John Richard White

Yu Xue

Yen Sen Ho

Judithann M Lee

Patrick McDevitt

Neil James Clarke

John J Trill

Christopher B Hopson

Zdenka Haskova

The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

Antigen binding proteins

This present invention relates to the use of the B1 domain of Protein G as an epitope tag for over-expression of proteins in mammalian cells.

Expression of protein GB1 domain fusion proteins in mammalian cells

Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed.

Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin &#x3b1;&#x3b2;receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of &#x3b1;&#x3b2;-mediated disorders, such as restenosis, in human patients.

[object Object]

The present invention provides a method for producing physiologically active human Interleukin-18 ('IL-18').

Method for preparing a physiologically active IL-18 polypeptide

Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.

Conjugates comprising human IL-18 and substitution mutants thereof

Anti-alphabeta3 humanized monoclonal antibodies

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human &#x3b1;subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Nucleic acids encoding anti-human &#x3b1;&#x3bd;&#x3b2;3 and &#x3b1;&#x3bd;&#x3b2;5 antibodies

The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC &lsqb;SEQ ID NO: 1&rsqb;, gro&agr;&lsqb;SEQ ID NO:2&rsqb;, gro&bgr;&lsqb;SEQ ID NO: 3&rsqb; or gro&ggr;&lsqb;SEQ ID NO: 4&rsqb; or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro&bgr; dimer chemokine.

Dimeric modified gro&bgr; protein

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Anti-human .alpha..sub.v .beta..sub.3 and .alpha..sub.v .beta..sub.5

The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], gro.alpha. [SEQ ID NO:2], gro.beta. [SEQ ID NO: 3] or gro.gamma. [SEQ ID NO: 4] or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro.beta. dimer chemokine.

Growing community of inventors

King of Prussia, PA, United States of America

Kyung Oh Johanson